Kaya Holdings, Inc. Psychedelics Subsidiary Taps Total Holistic Center™ to Develop Ketamine Treatment Model for Launch of Fifth Dimension Therapeutics™ Mind Care Clinics
February 14th, 2023
Psychedelics, Top News
FT. LAUDERDALE, FL /February 14, 2023 / Kaya Holdings, Inc., (“KAYS” or the “Company”) (OTCQB: KAYS), a pioneer in the U.S. cannabis industry, announced today that its subsidiary Fifth Dimension Therapeutics™ (FDT) has reached an agreement in principle with Florida-based Total Holistic Center™ (“Total Holistic”) to assist FDT with the development of its ketamine treatment model as a first step in the launch of its planned Fifth Dimension Therapeutics Mind Care Clinics and Telehealth Services.
Dr. Anya Temer of Total Holistic Center will be
developing treatment protocols for KAYS’
Ketamine Clinic and Telehealth Model to be Launched from
Holistic’s Boca Raton, Lake Worth, and Miami Beach Clinics
Initial plans call for co-locating the Company’s “Keta-Kaya” business within Total Holistic Center’s existing offices in Boca Raton, Fort Worth and Miami Beach upon the completion of required protocols. The hybrid Ketamine Clinic and Telehealth model will operate under the direction of Dr. Anya Temer, who will initially serve as FDT’s Medical Director in Florida.
Off label Ketamine Therapy has literally offered a new life to some
afflicted with treatment resistant depression (TRD) and PTSD, part of a
Global Suicide Epidemic that claims a life approximately every 40 seconds.
“This is our first step in the rollout of our business plan that calls for us to establish Fifth Dimension Therapeutics™ Mind Care Clinics and Telehealth Operations in multiple geographic locations” stated W. David Jones, a KAYS Senior Advisor and driving force behind the company’s developing psychedelic operations. “Ketamine, and soon psilocybin, offer breakthrough opportunities to effectively confront debilitating treatment resistant mental health conditions like depression and PTSD. It is the potential to help people while providing an exciting business opportunity motivates us.”
“I, and the entire Holistic team, are excited to work with the Kaya team and implement the Fifth Dimension Therapeutics ketamine therapy program. We look forward to working with them in and potentially beyond Florida,” said Dr. Anya Temer. “We are pleased to work together to innovate psychedelic care delivery.”
“We are working diligently to develop the treatment experiences we believe will most benefit our target customers. We believe that being able to work with Dr. Temer and the Total Holistic Center team will certainly contribute significantly to the high standards of treatment to which we aspire” concluded KAYS’ CEO Craig Frank. “As our cannabis activities shift to more rapidly growing overseas markets, we plan to focus more of our domestic U.S. efforts to establishing Fifth Dimension Therapeutics™.” The electricity in the air has returned”.
About Ketamine Therapy
Ketamine was FDA approved it as an anesthetic for people in 1970 and was used in treating injured soldiers on the battlefields in the Vietnam War. Since that time Emergency responders began to give it to an agitated patient who, for example, they have rescued from a suicide attempt, which has led Doctors to realize that the drug had powerful effects against depression and suicidal thoughts.
Today, Ketamine has been repurposed as an off-label analgesic and antidepressant. Extensive investigation of its rapid anti-depressive effects has been a breakthrough offering a potential lifesaving reprieve to those suffering from Treatment Resistant Depression (TRD) and has also been shown to reduce suicidal ideation in depressed patients at risk for suicide. Similarly, the administration of ketamine was effective at reducing depressive symptoms, acute suicidal behavior, and mood lability in youth with TRD and bipolar disease.
In 2019, the Food and Drug Administration (FDA) approved a nasal spray called esketamine, derived from ketamine—an anesthetic that has made waves for its surprising antidepressant effect. Intranasal esketamine is the only form of ketamine that has been FDA-approved as a treatment for TRD. However, Physicians have been prescribing racemic ketamine off-label to patients with depression for at least two decades. Additionally, Telehealth providers deliver oral tablets of ketamine that are taken at home for convenience with remote monitoring equipment and protocols for safety (also an off-label use). Using an approved drug for unapproved purposes (such as Ozempic for weight loss) is legal with the patient’s informed consent.
KAYS SHAREHOLDERS AND OTHER INTERESTED PARTIES
PLEASE UPDATE YOUR CONTACT INFORMATION
We routinely receive calls and emails from shareholders asking us questions about KAYS, so we are asking all KAYS shareholders to email us and confirm their contact info. Please email email@example.com with “KAYS shareholder update” in the subject line and include your name, address, phone number and number of shares you own so that we may make sure you receive all updates and can respond to any shareholder inquiries.
About Kaya Holdings, Inc.- (www.kayaholdings.com)
Kaya Holdings, Inc. (OTCQB:KAYS) is a Mind Care Company with longstanding operations as a touch-the-plant, vertically integrated legal cannabis business operating a number of majority-owned subsidiaries to retail, cultivate, produce and distribute premium medical and recreational cannabis products. The Company is evolving into a full mind care enterprise with the planned introduction psilocybin at-home and in-facility treatments, as permitted by law. KAYS is a fully reporting, US-based publicly traded company, listed for trading on the OTCQB Tier of the over-the-counter market under the symbol KAYS.
Summary of Operations
KAYS corporate structure includes the following four majority-owned subsidiaries, each responding to various demands and opportunities in the cannabis and psychedelic industry:
Fifth Dimension Therapeutics, Inc., serves as the Company’s operating branch to the psychedelic treatment sector, including operation of mushroom cultivation facilities, in-facility treatment centers, and at-home treatment programs.
Marijuana Holdings Americas, Inc. owns the Kaya Shack™ brand of licensed medical and recreational marijuana stores (www.kayashack.com) and the Kaya Farms™ brand of cannabis production and processing operations that operate in the United States.
Kaya Brands USA, Inc. owns a wide range of proprietary brands of cannabis extracts, oils, pre-rolls, topicals, food and beverages, cannaceuticals and related accessories.
Kaya Brands International, Inc., was founded to serve as the vehicle for the Company’s non-U.S. operations under development including retail franchising in Canada and cultivation activities in Greece and Israel.
KAYS is planning execution of its stated business objectives in accordance with current understanding of state and local laws and federal enforcement policies and priorities as it relates to cannabis and psychedelics. Potential investors and shareholders are cautioned that KAYS and subsidiaries including FTD will obtain advice of counsel prior to actualizing any portion of their business plan (including but not limited to license applications for the cultivation, distribution or sale of marijuana and psychedelic products, engaging in said activities or acquiring existing production/sales operations). Advice of counsel with regard to specific activities of KAYS, federal, state or local legal action or changes in federal government policy and/or state and local laws may adversely affect business operations and shareholder value.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
For more information, contact Investor Relations: info@kayaholdings.
SOURCE: Kaya Holdings
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.